Patents Assigned to The University of Virginia Patent Foundation
-
Publication number: 20240148765Abstract: Provided are methods for treating and/or preventing genotoxic stress-induced cardiac toxicity, which in some embodiments include administering to a subject an effective amount of an inhibitor of t-CH, of neutrophil activation, of neutrophil migration, or any combination thereof. In some embodiments, the genotoxic stress-induced cardiac toxicity results from exposure to one or more anti-tumor and/or anti-cancer therapies, including but not limited to treatment with one or more chemotherapeutics (e.g., doxorubicin) and/or treatment with radiation. In some embodiments, the genotoxic stress-induced cardiac toxicity, the chemotherapy-induced cardiac toxicity, the chemotherapy-induced heart damage, and/or the chemotherapy-induced reduction in cardiac function is characterized by a reduction in cardiac contractility, a thinning of a ventricular wall, a reduction in cardiomyocyte size, or any combination thereof.Type: ApplicationFiled: March 14, 2022Publication date: May 9, 2024Applicant: University of Virginia Patent FoundationInventors: Kenneth Walsh, Soichi Sano
-
Publication number: 20240138770Abstract: Embodiments can relate to systems and methods for automatically detecting sensor compression in continuous glucose monitoring in real time. A system may include at least one sensor and at least one processor in communication with the at least one sensor. The at least one processor is programmed or configured to cause the processor to retrieve first measurement data including at least one time series of blood glucose (BG) measurements, the at least one time series being measured by the at least one sensor while not subject to compression; receive, from the at least one sensor, second measurement data including at least one BG measurement; determine a clearance value between BG measurements based on the first measurement data and the second measurement data; and generate a signal output indicating that the at least one sensor is subject to compression based on the clearance value between BG measurements exceeding a predefined threshold.Type: ApplicationFiled: November 2, 2023Publication date: May 2, 2024Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Boris P. KOVATCHEV, Chiara FABRIS, Marcela MOSCOSO-VASQUEZ
-
Publication number: 20240144446Abstract: Embodiments can relate to a system for producing a digital image by automatically correcting for scattering and/or absorption effects in an original digital image. The system can include a processor. The system can include memory containing a computer program that when executed will cause the processor to receive radiance spectra of a digital image, and execute a Gaussian machine learning model. The system can generate a reflectance parameter by predicting a ground reflectance value based on a Gaussian probability distribution of radiance spectra. The system can solve for a conversion coefficient based on the reflectance parameter. The system can produce an altered digital image by at least one or more of removing, filtering, and/or altering data for at least one pixel of a digital image based on the conversion coefficient.Type: ApplicationFiled: October 26, 2023Publication date: May 2, 2024Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: William BASENER, Abigail BASENER
-
Publication number: 20240139415Abstract: Embodiments can relate to a system for automatically detecting sensor compression in continuous glucose monitoring including at least one sensor and at least one processor in communication with the at least one sensor, the at least one processor executing at least two machine learning models, wherein the at least one processor is programmed or configured to cause the processor to receive, from the at least one sensor, measurement data including at least one time series of blood glucose (BG) measurements measured by the at least one sensor, determine that the at least one time series of BG measurements is a candidate series including a compression artifact using a first machine learning model, and generate, using a second machine learning model, a signal output indicating that the at least one time series of BG measurements was obtained while the at least one sensor was subject to compression.Type: ApplicationFiled: November 2, 2023Publication date: May 2, 2024Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Boris P. KOVATCHEV, Benjamin J. LOBO
-
Publication number: 20240139354Abstract: Some embodiments relate to imageable radioisotopic microspheres. In some embodiments, the imageable microspheres are radiolabeled with imageable radioisotopes. In some embodiments, the imageable radioisotope is directly coupled to a surface of a substrate of the microsphere. In some embodiments, the imageable microspheres can be used as surrogate particles to predict the distribution of therapeutic microspheres comprising radiotherapeutic isotopes.Type: ApplicationFiled: January 8, 2024Publication date: May 2, 2024Applicants: Boston Scientific Medical Device Limited, University of Virginia Patent FoundationInventors: James Radford Stone, Kiel Douglas Neumann, Matthew Robert Dreher
-
Patent number: 11965810Abstract: An exemplary method and system is disclosed that facilitate the integration of multiplexed single-cell impedance cytometry in a high throughput format, which can be deployed upstream from microfluidic sample preparation and/or downstream to microfluidic cell separation. In exemplary method and system may employ impedance-based quantification of cell electrophysiology on the same microfluidic chip (i.e., “on-chip”) to provide distinguishing phenotypic information on the sample, without the need for additional sample handling, preparation or dilution steps as would be needed for other flow cytometry techniques.Type: GrantFiled: September 26, 2019Date of Patent: April 23, 2024Assignee: University of Virginia Patent FoundationInventors: Nathan Swami, John McGrath, Walter Varhue, Carlos Honrado, Vahid Farmehini, Yi Liu
-
Publication number: 20240127967Abstract: Methods of modeling the in vivo efficacy of drug combinations for the treatment or prevention of viral infection are described. The described methods combine data for single drugs and drug combinations from pharmacokinetic, pharmacodynamic, and viral dynamics models under a series of estimated in vivo drug potencies to provide predictions of the in vivo effects of the drug combinations. These predictions can be used to more accurately select drugs and drug treatment regimens that can be successful in controlling viral infection in animal studies, clinical trials and in medical or veterinary interventions. Also described is a method of treating or preventing filovirus infections using combinations of orally available drugs based on predictions from the modeling methods.Type: ApplicationFiled: February 9, 2022Publication date: April 18, 2024Applicants: University of Virginia Patent Foundation, Fred Hutchinson Cancer Research CenterInventors: Judith M. White, Shuang Xu, Joshua T. Schiffer, Gene G. Olinger, Courtney L. Finch, Julie Dyall, Stephen J. Polyak, Lisa Johansen
-
Patent number: 11957664Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.Type: GrantFiled: March 23, 2023Date of Patent: April 16, 2024Assignee: University of Virginia Patent FoundationInventor: Bankole A. Johnson
-
Patent number: 11957682Abstract: In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: June 27, 2022Date of Patent: April 16, 2024Assignee: University of Virginia Patent FoundationInventors: Hui Li, Zhongqiu Xie
-
Publication number: 20240121620Abstract: Embodiments relate to a dynamic spectrum access (DSA) system including a DSA transmitter configured to generate a complex signal for a secondary communication system, the complex signal being within a communication band A that is equal to or falls within a communication band B of a primary communication system. The complex signal includes a first signal and a second signal that is a repeat of the first signal. The power of the complex signal received at the secondary communication receiver is greater than the noise floor of the secondary communication system, but is equal to or less than the interference power from the primary communication. The DSA system includes a DSA receiver including a plurality of DSA antennas and a DSA signal processing module, the DSA signal processing module configured to perform canonical correlation analysis (CCA) on the complex signal.Type: ApplicationFiled: December 10, 2021Publication date: April 11, 2024Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Mohamed Salaheldeen IBRAHIM, Nikolaos Dimitrios Sidiropoulos
-
Publication number: 20240115729Abstract: Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOS: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen III-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.Type: ApplicationFiled: February 4, 2022Publication date: April 11, 2024Applicant: University of Virginia Patent FoundationInventors: Kimberly A. Kelly, Ph.D., Jessica Hung
-
Publication number: 20240117358Abstract: Provided herein is a previously unannotated IncRNA lying within exon six and 3?UTR of the LCK gene, labeled “HULLK” for Hormone-Upregulated IncRNA within LCK. HULLK is a novel IncRNA situated within the LCK gene that can serve as an oncogene in PCa. Accordingly, provided are methods and compositions for diagnosing and treating prostate cancer based on HULLK that regulates prostate cancer cell growth.Type: ApplicationFiled: October 16, 2023Publication date: April 11, 2024Applicant: University of Virginia Patent FoundationInventor: Daniel G. Gioeli
-
Patent number: 11950935Abstract: A system for generating a hypoglycemia risk signal associated with exercise-induced Hypoglycemia. The system can include a processor configured to obtain a blood glucose signal (BGstart), a ratio of absolute insulin on board over total daily insulin signal (IOBabs/TDI), and an initial glycemic slope signal (S0); generate a hypoglycemia risk signal based on a hypoglycemia prediction algorithm that determines the probability of a user being hypoglycemic during or after exercise based on the obtained BGstart, IOBabs/TDI and S0.Type: GrantFiled: February 8, 2023Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Marc D. Breton, Najib Ben-Brahim
-
Patent number: 11951303Abstract: The epicardial pacing system and related method includes an epicardial catheter configured to be disposed in the middle mediastinum of the thorax of a subject for use in electrical pacing of the heart at one or more locations on the epicardial surface. The epicardial pacing catheter may include at least one electrode whereby the electrode is insulated on at least one side to allow pacing of the heart without damage to adjacent anatomical structures.Type: GrantFiled: April 23, 2018Date of Patent: April 9, 2024Assignee: University of Virginia Patent FoundationInventors: Srijoy Mahapatra, George T. Gillies
-
Patent number: 11954578Abstract: Systems and methods for denoising a magnetic resonance (MR) image utilize an unsupervised deep convolutional neural network (U-DCNN). Magnetic resonance (MR) image data of an area of interest of a subject can be acquired, which can include noisy input images that comprise noise data and noise free image data. For each of the noisy input images, iterations can be run of a converging sequence in an unsupervised deep convolutional neural network. In each iteration, parameter settings are updated; the parameter settings are used in calculating a series of image feature sets with the U-DCNN. The image feature sets predict an output image. The converging sequence of the U-DCNN is terminated before the feature sets predict a respective output image that replicates all of the noise data from the noisy input image. Based on a selected feature set, a denoised MR image of the area of interest of the subject can be output.Type: GrantFiled: April 24, 2020Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Craig H Meyer, Xue Feng
-
Patent number: 11950877Abstract: A computerized system and method of modeling myocardial tissue perfusion can include acquiring a plurality of original frames of magnetic resonance imaging (MRI) data representing images of a heart of a subject and developing a manually segmented set of ground truth frames from the original frames. Applying training augmentation techniques to a training set of the originals frame of MRI data can prepare the data for training at least one convolutional neural network (CNN). The CNN can segment the training set of frames according to the ground truth frames. Applying the respective input test frames to a trained CNN can allow for segmenting an endocardium layer and an epicardium layer within the respective images of the input test frames. The segmented images can be used in calculating myocardial blood flow into the myocardium from segmented images of the input test frames.Type: GrantFiled: February 5, 2020Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Craig H. Meyer, Xue Feng, Michael Salerno
-
Patent number: 11951278Abstract: An insulin monitoring system includes one or more processors, one or more computer-readable storage devices, and program instructions stored on at least one of the one or more storage devices for execution by at least one of the one or more processors. The program instructions include: first program instructions to track, in real time, the amount of insulin active in a patient; second program instructions to calculate the amount of insulin need of the patient by tracking the patient's metabolic states; third program instructions to compare the insulin active in the patient with the insulin need of the patient; and fourth program instructions to determine an insulin fault level based on the comparison.Type: GrantFiled: March 15, 2022Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Marc D. Breton, Stephen D. Patek, Boris P. Kovatchev
-
Patent number: 11945825Abstract: The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.Type: GrantFiled: July 1, 2021Date of Patent: April 2, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Kyle Hoehn, Brandon Kenwood
-
Patent number: 11944665Abstract: In some embodiments herein, methods, compositions, and uses for modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease comprise by increasing flow via meningeal lymphatic vessels are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of inflammatory neurological disease be inhibiting or preventing immune cell migration through meningeal lymphatic vessels are described.Type: GrantFiled: May 31, 2017Date of Patent: April 2, 2024Assignee: University of Virginia Patent FoundationInventors: Jonathan Kipnis, Antoine Louveau, Sandro Da Mesquita
-
Publication number: 20240100081Abstract: It is disclosed herein that RPE degeneration in human cell culture and in mouse models is driven by a non-canonical inflammasome pathway that results in activation of caspase-4 (also known as caspase-11 in mouse) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-? (IFN-?) production and gasdermin D-dependent interleukin-18 (IL-18) secretion. Reduction of DICER1 or accumulation of Alu RNA triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Collectively, these data highlight an unexpected role for cGAS in responding to mobile element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial damage-induced NLRP3 activation, and expand the immune sensing repertoire of cGAS and caspase-4 to non-infectious human disease. Coupled with the unexpected result that caspase-4, gasdermin D, IFN-?, and cGAS are elevated in the RPE of human eyes with geographic atrophy, these findings also identify new targets for a major cause of blindness.Type: ApplicationFiled: May 12, 2023Publication date: March 28, 2024Applicant: University of Virginia Patent FoundationInventors: Jayakrishna Ambati, Nagaraj Kerur